What is the Point Guard in a dental practice?

The Point Guard is a PDA term for the provider — usually the owner — who originates a disproportionate share of a practice's diagnosed treatment without producing a proportionate share of its revenue. In one $10M, fifteen-provider practice, the owner performed 4.4% of exams and produced 4.8% of doctor production, but originated 24.6% of everything the practice proposed, at $10,632 per plan against associate plans of $875 to $1,393. He doesn't score; he distributes. Remove him and the comprehensive pipeline — implants, orthodontics, full-arch — is not handed to someone else. It stops being diagnosed.

How do buyers price key-person risk in a dental practice sale?

As transition insurance. Once a buyer's clinical diligence finds diagnostic dependency, the employment agreement gets longer, the earnout gets larger and its metric is tied to production the buyer now knows depends on one person's exam chair, and the holdback grows. A financial QoE often concludes 'low key-person risk' from production numbers alone; the buyer's clinical diligence — the layer institutional acquirers run and individual buyers skip — finds the dependency in a single query, and the terms are written accordingly.

What is an assist matrix?

A measurement most practices have never built: treatment planned by one provider and completed by another, drawn from the practice management system's treatment-plan provider and procedure provider fields. It quantifies how much of each associate's production originated in the Point Guard's exam chair, and it is the only number that proves the diagnostic pipeline is becoming distributed instead of merely claiming it. PDA runs it quarterly as part of the Clinical Quality of Earnings.

Financial Analytics

The Point Guard: The Key-Person Risk Financial Diligence Can't See

James DeLuca September 14, 2026 8 min read

John Stockton never led the Jazz in scoring. Karl Malone did, for fourteen straight seasons. Take Malone off that roster and Utah loses its best player. Take Stockton off it and Utah loses its offense, because almost every shot Malone took started in Stockton’s hands.

Some dental practices have Point Guards. Buyers rarely measure them. And that gap is one of the most expensive blind spots in dental M&A.

The Wrong Question

Every buyer asks the same question about key-person risk: what percentage of production is the owner?

In a $10M multi-provider practice I analyzed this month, the answer was 4.8%. The owner produced $393,695 of $8.2M in doctor production. The top three associates carried 62%. On the standard read, this is a low-dependency practice. The kind a buyer can transition without much transition insurance, the kind that earns more cash at close and a smaller earnout.

The standard read is wrong. It’s measuring who scores.

The Right Question

Who creates the production?

The owner performed 482 exams last year, 4.4% of the practice’s exam volume. From those 482 exams, he proposed $5,124,510 of treatment: 24.6% of everything the entire practice diagnosed, from under 5% of its exams. His plans averaged $10,632. The associates’ plans averaged $875 to $1,393.

Provider	Share of exams	Share of proposed treatment	Average plan	Share of production
Owner (the Point Guard)	4.4%	24.6%	$10,632	4.8%
Top three associates	77.7%	45.6%	$875 – $1,393	62.0%

Source: Precision Dental Analytics Clinical Quality of Earnings, redacted exemplar — 10,859 exams, $20.8M proposed, $8.2M doctor production, trailing twelve months.

That is not a difference in style. It is a difference in what gets diagnosed. He diagnoses comprehensively, implants, orthodontics, full-arch, the specialist days that make a practice worth a multiple. They diagnose the tooth in front of them. He doesn’t score. He distributes. And every high-value case the associates complete started in his exam chair.

Remove him and the comprehensive pipeline doesn’t get handed to someone else. It stops being diagnosed. The associates don’t suddenly start seeing full-mouth cases; they keep diagnosing single teeth at $1,100 a plan. The practice doesn’t collapse. It reverts. Over the next twelve to twenty-four months, the high-margin work thins out, the specialist days empty. At very best the $10M practice becomes an $8M practice with the same overhead, at worst it begins losing providers who grow frustrated with their compensation cratering. That’s a slower, less visible failure than losing the top producer, which is exactly why some never see it coming.

Why Financial Diligence Misses It

Revenue by provider appears in every Quality of Earnings report ever written. Diagnosis by provider appears in almost none of them.

The dependency doesn’t live in the ledger. It lives in the treatment-plan provider field of the practice management software that shows who planned the case, not who completed it. A CPA’s normalization can’t see it. A broker’s prospectus won’t show it. The buyer’s financial QoE will conclude “low key-person risk” from the production numbers, and then the buyer’s clinical diligence, the part institutional acquirers run and individual buyers skip, will find it in a single query.

I call it diagnostic dependency, as distinct from production dependency. Production dependency asks who does the work. Diagnostic dependency asks who decides what work gets proposed. A practice can have almost none of the first and be entirely captive to the second. It is the provider-side counterpart to the Clinical Ledger’s question — who sees the exams, who presents, who completes — and it only shows up when someone reads the exam chair instead of the production report.

How Buyers Price It Once They See It

As transition insurance, the same instrument I wrote about two weeks ago. The employment agreement gets longer. The earnout gets larger and its metric gets tied to production the buyer now knows depends on one person’s exam chair. The holdback grows. The owner who thought he’d built a practice that runs without him discovers, at the LOI, that it runs without his hands but not without his eyes. Then the terms are written accordingly.

The Other Edge of the Same Finding

Here is where it gets uncomfortable, because the assist numbers cut both ways.

His $5.1M of proposed treatment converted at 9.5%. That’s $4.5M diagnosed and never accepted — in one year, from one provider.

A buyer reads that two ways, and a seller needs to know both before the buyer does. The first reading: it’s the largest conversion opportunity in the practice. Install a treatment coordinator and a financing conversation, lift the close rate from 9.5% to 25%, and that’s roughly $700,000 of production with no new patients. Upside the buyer will model, keep, and pay the seller nothing for.

The second reading is less charitable: a 9.5% close rate on $10,000+ plans invites the question of whether the diagnoses are clinically driven or consult-driven, and a compliance team will sample his charts specifically to find out. Documented clinical rationale is the only defense against the second reading, a presentation system is the answer to the first. Neither exists by accident.

The Remediation

The model is deliberate, I’ve built it inside DSOs. It’s efficient and agnostic when it’s a system. The failure is when it’s a person.

Making it a system means three things. Associates in the exam chair alongside “the Point Guard” on a defined runway, learning to diagnose comprehensively rather than incrementally. The Point Guard’s diagnostic protocols documented: what he looks for, what he plans, and why. The assist matrix is a measurement most practices have never built, treatment planned by one provider, completed by another, from the PMS. It’s the only number that proves the pipeline is becoming distributed instead of just claiming it.

In a multi-provider practice, do that twelve to twenty-four months before market and it becomes a system the buyer pays for. Skip it and he’s a clause the buyer writes. It is one of the eighteen items on the remediation roadmap that closes every Clinical Quality of Earnings — and one of the few that a buyer will recognize, because the ones who’ve run the model know exactly what it’s worth.

The Bottom Line

The buyer isn’t only asking who scores. They’re asking who runs the offense the day you retire, and whether the answer is a person or a process. The two price very differently.

Know your Point Guard before they do.

Frequently Asked

Questions

What is the Point Guard in a dental practice?: The Point Guard is a PDA term for the provider — usually the owner — who originates a disproportionate share of a practice's diagnosed treatment without producing a proportionate share of its revenue. In one $10M, fifteen-provider practice, the owner performed 4.4% of exams and produced 4.8% of doctor production, but originated 24.6% of everything the practice proposed, at $10,632 per plan against associate plans of $875 to $1,393. He doesn't score; he distributes. Remove him and the comprehensive pipeline — implants, orthodontics, full-arch — is not handed to someone else. It stops being diagnosed.
What is diagnostic dependency, and how is it different from production dependency?: Production dependency asks who does the work: what percentage of revenue a single provider produces. Diagnostic dependency asks who decides what work gets proposed: what share of diagnosed treatment originates from one provider's exam chair. A practice can have almost none of the first and be entirely captive to the second. Revenue by provider appears in every Quality of Earnings report; diagnosis by provider appears in almost none, because the dependency lives in the treatment-plan provider field of the practice management software, not the ledger.
How do buyers price key-person risk in a dental practice sale?: As transition insurance. Once a buyer's clinical diligence finds diagnostic dependency, the employment agreement gets longer, the earnout gets larger and its metric is tied to production the buyer now knows depends on one person's exam chair, and the holdback grows. A financial QoE often concludes 'low key-person risk' from production numbers alone; the buyer's clinical diligence — the layer institutional acquirers run and individual buyers skip — finds the dependency in a single query, and the terms are written accordingly.
What is an assist matrix?: A measurement most practices have never built: treatment planned by one provider and completed by another, drawn from the practice management system's treatment-plan provider and procedure provider fields. It quantifies how much of each associate's production originated in the Point Guard's exam chair, and it is the only number that proves the diagnostic pipeline is becoming distributed instead of merely claiming it. PDA runs it quarterly as part of the Clinical Quality of Earnings.
How do you reduce diagnostic dependency before selling a practice?: Make comprehensive diagnosis a system rather than a person, twelve to twenty-four months before market. Three things: associates in the exam chair alongside the Point Guard on a defined runway, learning to diagnose comprehensively rather than incrementally; the Point Guard's diagnostic protocols documented — what he looks for, what he plans, and why; and the assist matrix run quarterly to prove the change is holding. Done early, the Point Guard becomes a system the buyer pays for. Skipped, he becomes a clause the buyer writes.